Lincomycin Hydrochloride Injection passes generic drug consistency evaluation
September 11, 2026
Source: drugdu
25
On September 10, Shanghai Pharmaceuticals announced that its subsidiary, Shanghai Hefeng Pharmaceutical Co., Ltd., recently received the "Drug Supplementary Application Approval Notice" for Lincomycin Hydrochloride Injection issued by the National Medical Products Administration (NMPA). The drug has passed the generic drug quality and efficacy consistency evaluation. This drug is indicated for respiratory tract infections, skin and soft tissue infections, etc., caused by susceptible bacteria such as Streptococcus, Pneumococcus, and Staphylococcus aureus.
Source: Eastmoney | https://finance.eastmoney.com/a/202609103870825889.html
By editor
Copyright©2026 Ddu. All rights reserved.
Read more on
- Five innovative drugs approved for marketing September 11, 2026
- Subsidiary’s novel coronavirus mRNA vaccine receives drug registration certificate September 11, 2026
- CSPC Pharmaceutical Group’s innovative chemical drug SYH2083 eye drops approved for clinical trials in China September 11, 2026
- Novel influenza virus mRNA vaccine approved for clinical trials September 11, 2026
- Yuanda and Weixin’s two adsorbed acellular pertussis-diphtheria-tetanus combination vaccines simultaneously approved for clinical trials September 11, 2026
your submission has already been received.
OK
Subscribe
Please enter a valid Email address！
Submit
The most relevant industry news & insight will be sent to you every two weeks.
